Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials

AIM: To investigate the efficacy and safety of initiating insulin degludec/liraglutide (IDegLira) in patients with type 2 diabetes (T2D) who had discontinued pretrial sulphonylureas (SUs) or dipeptidyl peptidase‐4 inhibitors (DPP4is) versus patients not previously treated with these regimens. MATERI...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Obes Metab
Main Authors: Janez, Andrej, Őrsy, Petra, Stachlewska, Karolina, Salvesen‐Sykes, Karen, Billings, Liana K., Philis‐Tsimikas, Athena
Format: Artigo
Sprog:Inglês
Udgivet: Blackwell Publishing Ltd 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079143/
https://ncbi.nlm.nih.gov/pubmed/31858673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13944
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker